Skip to main content

Vaxcyte, Inc 10-Q for FY2026 Q3

Vaxcyte, Inc. (PCVX)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 04, 2026

About this 10-Q

Vaxcyte, Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

VAX-31 met all prespecified primary endpoints in the pivotal adult Phase 3 OPUS-1 trial and was well tolerated. Vaxcyte raised approximately $1.15 billion in October 2026 and held $2.3 billion of cash, cash equivalents and investments as of September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$297.06M
compared with a net loss of $212.83M a year earlier
Diluted EPS
-$1.99
compared with -$1.56 a year earlier